FDA Rejects Replimune's Drug Application RP1 Amid Controversy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy REPL?
Source: stocktwits
- FDA Drug Rejection: The FDA has once again rejected Replimune's melanoma drug RP1, citing insufficient data to provide substantial evidence of effectiveness, leading to a 13% drop in Replimune's stock on Tuesday, reflecting market pessimism about the company's future prospects.
- Commissioner Defense: FDA Commissioner Marty Makary defended the agency in an interview, asserting that there were no 'corrupt sweetheart deals' with Replimune and noted that three independent teams reached the same conclusion, indicating that the drug's effectiveness remains unclear, showcasing the FDA's rigor in the drug approval process.
- Medical Community Outcry: Doctors criticized the FDA's decision in an opinion piece in The Wall Street Journal, highlighting that the initial panel had recommended approval for RP1, which was later overturned by the then-FDA biologics chief, reflecting inconsistencies in FDA decision-making that could impact patient treatment options.
- Replimune's Counterargument: Replimune expressed dissatisfaction with the FDA's decision, with CEO Sushil Patel stating that the drug's unavailability is not due to its failure but rather the inefficiency of the regulatory system, emphasizing the company's challenging position in the drug approval process.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REPL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REPL
Wall Street analysts forecast REPL stock price to rise
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 3.030
Low
3.00
Averages
11.43
High
18.00
Current: 3.030
Low
3.00
Averages
11.43
High
18.00
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Rejects Replimune's Drug Application RP1 Amid Controversy
- FDA Drug Rejection: The FDA has once again rejected Replimune's melanoma drug RP1, citing insufficient data to provide substantial evidence of effectiveness, leading to a 13% drop in Replimune's stock on Tuesday, reflecting market pessimism about the company's future prospects.
- Commissioner Defense: FDA Commissioner Marty Makary defended the agency in an interview, asserting that there were no 'corrupt sweetheart deals' with Replimune and noted that three independent teams reached the same conclusion, indicating that the drug's effectiveness remains unclear, showcasing the FDA's rigor in the drug approval process.
- Medical Community Outcry: Doctors criticized the FDA's decision in an opinion piece in The Wall Street Journal, highlighting that the initial panel had recommended approval for RP1, which was later overturned by the then-FDA biologics chief, reflecting inconsistencies in FDA decision-making that could impact patient treatment options.
- Replimune's Counterargument: Replimune expressed dissatisfaction with the FDA's decision, with CEO Sushil Patel stating that the drug's unavailability is not due to its failure but rather the inefficiency of the regulatory system, emphasizing the company's challenging position in the drug approval process.
See More
FDA Commissioner Defends Drug Rejections Amid Pressure
- Defense of Drug Rejections: FDA Commissioner Marty Makary defended recent drug rejections in a CNBC interview, emphasizing his commitment to serving the American public rather than specific companies, thereby reinforcing the FDA's independence and scientific integrity.
- High-Profile Drug Case: The FDA's rejection of a melanoma drug candidate from Replimune highlights the agency's stringent standards, as Makary noted that three independent teams reached the same conclusion regarding the drug's efficacy and safety.
- Internal Agency Pressure: A Bloomberg report described a climate of 'paranoia, turmoil, and backlash' within the FDA under Makary's leadership, indicating significant internal pressure that could impact future drug approval decisions.
- Historical Lessons: Makary referenced past instances where FDA commissioners overruling scientists led to disastrous outcomes, citing the approval of Aduhelm and a Covid-19 vaccine for young children, thus underscoring the critical importance of scientific evaluation in drug approvals.
See More
FDA Commissioner Makary Defends Drug Rejections Amid Controversy
- Drug Rejection Controversy: FDA Commissioner Makary defended the agency's rejection of Replimune's melanoma drug candidate during a CNBC interview, asserting that three independent teams reached the same conclusion, indicating that the FDA's scientific review process remains free from corrupt influences.
- Intensifying Media Pressure: As The Wall Street Journal published multiple opinion pieces criticizing Makary's performance in the Trump administration, the FDA faces mounting public scrutiny, reflecting a climate of 'paranoia, turmoil, and backlash' within the agency.
- Importance of Scientific Review: Makary emphasized that overruling FDA scientists has led to disastrous outcomes, citing the approval of the Alzheimer's drug Aduhelm and the clearance of a Covid-19 vaccine booster for young children, underscoring the necessity of adhering to scientific evaluations.
- Challenge to Public Trust: Amidst the pressures facing the FDA, Makary reiterated his support for scientists, stating his commitment to serving the public interest rather than specific companies, aiming to restore public confidence in the FDA.
See More
Pomerantz Investigates Securities Fraud Claims Against Replimune Group, Inc.
- Investigation Launched: Pomerantz LLP is investigating claims on behalf of Replimune Group, Inc. investors regarding potential securities fraud or other unlawful business practices, highlighting serious concerns about corporate governance.
- FDA Response: On April 10, 2026, Replimune announced it received a Complete Response Letter (CRL) from the FDA due to insufficient data supporting its Biologics License Application (BLA), indicating significant disagreements with the agency.
- Stock Price Plunge: Following this announcement, Replimune's stock price fell by $3.06, or 64.29%, closing at $1.70 per share on April 13, 2026, reflecting a pessimistic outlook from the market regarding the company's future.
- Legal Implications: Pomerantz LLP, a prominent firm in securities class action litigation, has a long history of advocating for victims of securities fraud, which could have significant legal ramifications for Replimune moving forward.
See More
Replimune Group Under Investigation for Securities Fraud
- FDA Response Letter: On April 10, 2026, Replimune received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application for RP1 in combination with nivolumab for advanced melanoma, indicating a disagreement over the sufficiency of the data set, which could hinder future drug approval processes.
- Stock Price Plunge: Following this announcement, Replimune's stock price fell by $3.06, or 64.29%, closing at $1.70 per share on April 13, 2026, reflecting extreme market pessimism regarding the company's future prospects.
- Investor Alert: Pomerantz LLP is investigating whether Replimune and its executives engaged in securities fraud or other unlawful business practices, advising investors to contact the firm for more information, potentially leading to a class action lawsuit.
- Legal Background: Pomerantz LLP, a premier firm in corporate and securities class litigation with over 85 years of experience, focuses on fighting for the rights of victims of securities fraud, indicating that Replimune faces significant legal risks that could result in substantial financial losses.
See More
FDA Rejects Replimune's Melanoma Drug RP1 Again
- FDA Rejection: The FDA has once again refused to approve Replimune's melanoma drug RP1 this month, citing insufficient data to provide “substantial evidence of effectiveness,” which significantly impacts Replimune's market prospects.
- Call for Change: Melanoma doctors criticized the FDA's decision in an opinion piece in The Wall Street Journal, noting that the initial review panel recommended approval, but this was overruled by the FDA's biologics chief, highlighting inconsistencies in FDA decision-making.
- Market Reaction: Despite the FDA's rejection, Replimune's shares surged 22% after doctors expressed disappointment, indicating that there remains potential demand for the drug and support from the medical community.
- Future Outlook: Replimune has the option to resubmit or withdraw its application within a year, and the FDA's rejection has not changed, making future clinical trials and data critical to determining the drug's fate.
See More
FDA Rejects Replimune's Drug Application RP1 Amid Controversy
- FDA Drug Rejection: The FDA has once again rejected Replimune's melanoma drug RP1, citing insufficient data to provide substantial evidence of effectiveness, leading to a 13% drop in Replimune's stock on Tuesday, reflecting market pessimism about the company's future prospects.
- Commissioner Defense: FDA Commissioner Marty Makary defended the agency in an interview, asserting that there were no 'corrupt sweetheart deals' with Replimune and noted that three independent teams reached the same conclusion, indicating that the drug's effectiveness remains unclear, showcasing the FDA's rigor in the drug approval process.
- Medical Community Outcry: Doctors criticized the FDA's decision in an opinion piece in The Wall Street Journal, highlighting that the initial panel had recommended approval for RP1, which was later overturned by the then-FDA biologics chief, reflecting inconsistencies in FDA decision-making that could impact patient treatment options.
- Replimune's Counterargument: Replimune expressed dissatisfaction with the FDA's decision, with CEO Sushil Patel stating that the drug's unavailability is not due to its failure but rather the inefficiency of the regulatory system, emphasizing the company's challenging position in the drug approval process.
See More
FDA Commissioner Defends Drug Rejections Amid Pressure
- Defense of Drug Rejections: FDA Commissioner Marty Makary defended recent drug rejections in a CNBC interview, emphasizing his commitment to serving the American public rather than specific companies, thereby reinforcing the FDA's independence and scientific integrity.
- High-Profile Drug Case: The FDA's rejection of a melanoma drug candidate from Replimune highlights the agency's stringent standards, as Makary noted that three independent teams reached the same conclusion regarding the drug's efficacy and safety.
- Internal Agency Pressure: A Bloomberg report described a climate of 'paranoia, turmoil, and backlash' within the FDA under Makary's leadership, indicating significant internal pressure that could impact future drug approval decisions.
- Historical Lessons: Makary referenced past instances where FDA commissioners overruling scientists led to disastrous outcomes, citing the approval of Aduhelm and a Covid-19 vaccine for young children, thus underscoring the critical importance of scientific evaluation in drug approvals.
See More
FDA Commissioner Makary Defends Drug Rejections Amid Controversy
- Drug Rejection Controversy: FDA Commissioner Makary defended the agency's rejection of Replimune's melanoma drug candidate during a CNBC interview, asserting that three independent teams reached the same conclusion, indicating that the FDA's scientific review process remains free from corrupt influences.
- Intensifying Media Pressure: As The Wall Street Journal published multiple opinion pieces criticizing Makary's performance in the Trump administration, the FDA faces mounting public scrutiny, reflecting a climate of 'paranoia, turmoil, and backlash' within the agency.
- Importance of Scientific Review: Makary emphasized that overruling FDA scientists has led to disastrous outcomes, citing the approval of the Alzheimer's drug Aduhelm and the clearance of a Covid-19 vaccine booster for young children, underscoring the necessity of adhering to scientific evaluations.
- Challenge to Public Trust: Amidst the pressures facing the FDA, Makary reiterated his support for scientists, stating his commitment to serving the public interest rather than specific companies, aiming to restore public confidence in the FDA.
See More
Pomerantz Investigates Securities Fraud Claims Against Replimune Group, Inc.
- Investigation Launched: Pomerantz LLP is investigating claims on behalf of Replimune Group, Inc. investors regarding potential securities fraud or other unlawful business practices, highlighting serious concerns about corporate governance.
- FDA Response: On April 10, 2026, Replimune announced it received a Complete Response Letter (CRL) from the FDA due to insufficient data supporting its Biologics License Application (BLA), indicating significant disagreements with the agency.
- Stock Price Plunge: Following this announcement, Replimune's stock price fell by $3.06, or 64.29%, closing at $1.70 per share on April 13, 2026, reflecting a pessimistic outlook from the market regarding the company's future.
- Legal Implications: Pomerantz LLP, a prominent firm in securities class action litigation, has a long history of advocating for victims of securities fraud, which could have significant legal ramifications for Replimune moving forward.
See More
Replimune Group Under Investigation for Securities Fraud
- FDA Response Letter: On April 10, 2026, Replimune received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application for RP1 in combination with nivolumab for advanced melanoma, indicating a disagreement over the sufficiency of the data set, which could hinder future drug approval processes.
- Stock Price Plunge: Following this announcement, Replimune's stock price fell by $3.06, or 64.29%, closing at $1.70 per share on April 13, 2026, reflecting extreme market pessimism regarding the company's future prospects.
- Investor Alert: Pomerantz LLP is investigating whether Replimune and its executives engaged in securities fraud or other unlawful business practices, advising investors to contact the firm for more information, potentially leading to a class action lawsuit.
- Legal Background: Pomerantz LLP, a premier firm in corporate and securities class litigation with over 85 years of experience, focuses on fighting for the rights of victims of securities fraud, indicating that Replimune faces significant legal risks that could result in substantial financial losses.
See More
FDA Rejects Replimune's Melanoma Drug RP1 Again
- FDA Rejection: The FDA has once again refused to approve Replimune's melanoma drug RP1 this month, citing insufficient data to provide “substantial evidence of effectiveness,” which significantly impacts Replimune's market prospects.
- Call for Change: Melanoma doctors criticized the FDA's decision in an opinion piece in The Wall Street Journal, noting that the initial review panel recommended approval, but this was overruled by the FDA's biologics chief, highlighting inconsistencies in FDA decision-making.
- Market Reaction: Despite the FDA's rejection, Replimune's shares surged 22% after doctors expressed disappointment, indicating that there remains potential demand for the drug and support from the medical community.
- Future Outlook: Replimune has the option to resubmit or withdraw its application within a year, and the FDA's rejection has not changed, making future clinical trials and data critical to determining the drug's fate.
See More
